{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=14",
    "query": {
      "condition": "Stage IV Skin Melanoma",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 654,
    "total_pages": 66,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T05:28:21.579Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04557956",
      "title": "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Tazemetostat Hydrobromide",
          "type": "DRUG"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-08-19",
      "completion_date": "2027-03-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 17,
      "location_summary": "Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557956"
    },
    {
      "nct_id": "NCT02796352",
      "title": "A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "High dose bolus interleukin-2 (HD IL2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ahmad Tarhini",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-09",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2018-04-20",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796352"
    },
    {
      "nct_id": "NCT03617328",
      "title": "Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "6MHP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA-51",
          "type": "DRUG"
        },
        {
          "name": "polyICLC",
          "type": "DRUG"
        },
        {
          "name": "CDX-1127",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2018-11-13",
      "completion_date": "2024-01-19",
      "has_results": false,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 2,
      "location_summary": "Charlottesville, Virginia • Richmond, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03617328"
    },
    {
      "nct_id": "NCT06075524",
      "title": "Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Locally Advanced Lung Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Metastatic Lung Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2015-06-15",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06075524"
    },
    {
      "nct_id": "NCT00072189",
      "title": "A Phase II Study of UCN-01 in Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "7-hydroxystaurosporine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2003-11",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2015-03-02",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072189"
    },
    {
      "nct_id": "NCT00003568",
      "title": "Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-11",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Chicago, Illinois • Maywood, Illinois + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003568"
    },
    {
      "nct_id": "NCT00135408",
      "title": "A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab+ Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab+ Budesonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2005-12",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135408"
    },
    {
      "nct_id": "NCT00295958",
      "title": "LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Non-melanomatous Skin Cancer"
      ],
      "interventions": [
        {
          "name": "LMB-2 immunotoxin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2005-12",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2012-06-14",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295958"
    },
    {
      "nct_id": "NCT00006385",
      "title": "Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-11-08",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 32,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006385"
    },
    {
      "nct_id": "NCT02327390",
      "title": "Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage IIIC Skin Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "lymph node",
          "type": "PROCEDURE"
        },
        {
          "name": "X-ACT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2015-03-17",
      "completion_date": "2016-07-18",
      "has_results": false,
      "last_update_posted_date": "2018-12-06",
      "last_synced_at": "2026-10-14T05:28:21.579Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02327390"
    }
  ]
}